We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ONC market cap is 1.25M. The company's latest EPS is GBP -0.0453 and P/E is -0.37.
| Year End 31 August 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 509k | 3.72M | 3.79M | 2.11M | 2.74M |
| Operating Income | -9.85M | -5.18M | -10.01M | -5.01M | -3.23M |
| Net Income | -8.46M | -4.99M | -11.39M | 4.1M | -3.63M |
| Year End 31 August 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 10.32M | 19.36M | 10.16M | 8.44M | 4.9M |
| Total Liabilities | 10.51M | 14.13M | 14.34M | 7.78M | 7.3M |
| Total Equity | -194k | 5.23M | -4.18M | 657k | -2.4M |
| Year End 31 August 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -8.9M | -4.53M | -6.87M | -6.79M | -3.38M |
| Investing | 347k | -856k | -931k | 11.58M | 1.16M |
| Financing | 7.46M | 9.78M | 652k | -3.02M | -71k |
| Market Cap | 1.25M |
| Price to Earnings Ratio | -0.37 |
| Price to Sales Ratio | 0.49 |
| Price to Cash Ratio | 1.59 |
| Price to Book Ratio | -0.56 |
| Dividend Yield | - |
| Shares Outstanding | 80.14M |
| Average Volume (1 week) | 332.29k |
| Average Volume (1 Month) | 794.89k |
| 52 Week Change | -91.97% |
| 52 Week High | 30.20 |
| 52 Week Low | 1.20 |
| Spread (Intraday) | 0.67 (35.26%) |
| Company Name | Oncimmune Holdings Plc |
| Address |
medicity - d6 building nottingham NG90 6BH |
| Website | https://www.oncimmune.com |
| Industry | medical laboratories (8071) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
